DOCSLIB.ORG

Clinical Lung Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Lung Cancer CLINICAL LUNG CANCER AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.1 • Guide for Authors p.4 ISSN: 1525-7304 DESCRIPTION . Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center IMPACT FACTOR . 2020: 4.785 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . Scopus Embase CINAHL Chemical Abstracts Ovid EBSCOhost PubMed/Medline EDITORIAL BOARD . Editor-in-Chief Antoinette Wozniak, Pittsburgh, Pennsylvania, United States of America AUTHOR INFORMATION PACK 27 Sep 2021 www.elsevier.com/locate/jclc 1 Senior Associate Editors Shirish Gadgeel, Henry Ford Cancer Institute - Henry Ford Hospital, Department of Internal Medicine, Detroit, Michigan, United States of America Laurie Gaspar, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States of America Balazs Halmos, Montefiore Medical Center, Bronx, New York, United States of America Friedrich Knollmann, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States of America Jonathan Riess, University of California Davis School of Medicine, Sacramento, California, United States of America Inderpal (Netu) S. Sarkaria, University of Pittsburgh Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania, United States of America Associate Editors David T. Cooke, University of California Davis Health System, Sacramento, California, United States of America Walter J. Curran Jr., Emory University School of Medicine, Philadelphia, Pennsylvania, Georgia, United States of America Corey J. Langer, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America Tony S. Mok, The Chinese University of Hong Kong Department of Clinical Oncology, Hong Kong, Hong Kong, China Mary Redman, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Giorgio V. Scagliotti, University of Turin, Torino, Italy Publisher Angela Carmona, Philadelphia, Pennsylvania, United States of America Editorial Board Alex A. Adjei, Mayo Clinic Rochester, Buffalo, New York, Minnesota, United States of America Area of expertise - Medical oncology, Clinical pharmacology, Drug development, Translational research Arya Amini, City of Hope Comprehensive Cancer Center Duarte, Duarte, California, United States of America Radiation Oncology Paul Baas, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands Development of new therapies and the treatment of lung cancer and malignant mesothelioma Paolo Bironzo, University of Turin, Torino, Italy Immunotherapy and solid tumors Collin Blakely, University of California San Francisco, San Francisco, California, United States of America Medical Oncology; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Michael Boyer, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia Conjoint Chair of Medical Oncology (Thoracic Oncology); new anticancer drugs for the treatment of lung cancer Elisabeth Brambilla, University Grenoble Alpes, Grenoble, France lung tumor pathology Paul A. Bunn, University of Colorado, Aurora, Colorado, USA Translational research in lung cancer; identifying novel diagnostics and treatment strategies Timothy Burns, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America Medical Oncology; KRAS mutant non-small cell lung cancer; EGFR mutant lung cancer Brett Carter, University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology and Nutrition, Houston, Texas, United States of America Imaging; Diagnostic Imaging; Interventional Radiology Wei Chen, Wayne State University, Detroit, Michigan, United States of America Sanja Dacic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America Pathology Suzanne Dahlberg, Harvard Medical School, Boston, Massachusetts, United States of America Biostatistics & Computational Biology Justin Gainor, Harvard Medical School, Boston, Massachusetts, USA Design of clinical trials evaluating novel therapeutics for molecularly-defined subsets of non-small cell lung cancer; translational research Giuseppe Giaccone, Georgetown University, Georgetown, Maryland, District of Columbia, United States of America Developmental therapeutics; thymoma Glenwood Goss, Ottawa Hospital, Ottawa, Ontario, Canada Early cancer drug development and thoracic oncology Koichi Goto, National Cancer Center Higashi Hospital, Chiba, Japan Primary lung cancer, mediastinal tumors, and pleural tumors John Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America AUTHOR INFORMATION PACK 27 Sep 2021 www.elsevier.com/locate/jclc 2 Molecular drivers of lung cancer, identification of predictive biomarkers of drug sensitivity, and identification of mechanisms of therapeutic resistance and novel strategies to overcome resistance Fred Hirsch, University of Colorado Denver, Denver, Colorado, United States of America Steven Kao, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia Niki Karachaliou, Sacred Heart Hospital, Barcelona, Spain Medical Oncology; Translational Research Edward Kim, Levine Cancer Institute, Charlotte, North Carolina, United States of America Chair of the Department of Solid Tumor Oncology; thoracic cancer and cancers of the head and neck; molecular prognostication for lung cancer Feng-Ming (Spring) Kong, Case Western Reserve University, Cleveland, Ohio, United States of America Radiation Oncology Zhang Li, Sun Yat-Sen University, Guangzhou, China Clinical trials in lung cancer, new therapeutics, molecular markers Philip Mack, University of California Davis Medical Center, Davis, California, United States of America Molecular biology and molecular pharmacology studies; basic and translational research; molecular and cellular effects of novel anticancer agents Christian Manegold, University Medical Centre Mannheim Department of Surgery, Mannheim, Germany Surgery Daniel Morgensztern, Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States of America Medical Oncology; Thoracic malignancies Sai-Hong Ignatius Ou, University of California Irvine, Irvine, California, United States of America Area of expertise - Nasopharyngeal Carcinoma, Head and Neck Cancer, Thoracic malignancies, Esophageal carcinoma, Targeted therapy David Planchard, Gustave Roussy Department of Oncological Medicine, Villejuif, France Genomic analysis (and high-throughput technologies) to drive lunch cancer patients to specific targeted agents Suresh Ramalingam, Emory University School of Medicine, Atlanta, Georgia, United States of America Immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation Karen Reckamp, Cedars-Sinai Medical Center, Los Angeles, California, United States of America Jordi Remon, HM Delfos, Barcelona, Spain Medical Oncology; genomic characterization by liquid biopsies, as well as, the improvement in therapeutic strategies in thymic malignancies and mechanisms of resistance in small cell lung cancers Jill Siegfried, University of Pittsburgh, Rochester, Minnesota, Pennsylvania, United States of America Pharmacology; lung cancer biology and experimental therapeutics, focusing on targeting growth factors and hormone signaling that control lung cancer cell proliferation to treat lung cancer, and how immunotherapy can be enhanced by targeted therapy Thomas Stinchcombe, Duke University School of Medicine, Durham, North Carolina, United States of America Clinical care, clinical trials, and developing new therapies; Medical Oncology Kenichi Suda, Kindai University ,Faculty of Medicine, Division of Thoracic Surgery, Department of Surgery, Osaka, Japan EGFR mutation; Acquired resistance; Neoadjuvant therapy; Molecular target; Thoracic surgery Stephen Swisher, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America Thoracic and Cardiovascular Surgery Masahiro Tsuboi, Tokyo Medical University, Shinjuku-Ku, Japan Thoracic Surgery Liza Villaruz, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America Medical Oncology; lung cancer and thoracic malignancies Jie Wang, Peking University, Beijing, China Clinical trials in lung cancer, new therapeutics, molecular markers Maria Werner-Wasik, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States of America Radiation Yi-Long Wu, Guangdong Provincial People's Hospital, Guangzhou, China Multidisciplinary therapy and translational medicine
Load more

Recommended publications
  • The State of Lung Cancer Research: a Global Analysis
    ORIGINAL ARTICLE The State of Lung Cancer Research: A Global Analysis Ajay Aggarwal, MD, MSc,a,* Grant Lewison, PhD,a,b Saliha Idir, MSc,c Matthew Peters, MD,d Carolyn Aldige,e Win Boerckel, MBA,f Peter Boyle, PhD,g Edward L. Trimble, MD, MPH,h Philip Roe, PhD,b Tariq Sethi, MD, PhD,i Jesme Fox, MD,j Richard Sullivan, MD, PhDa aInstitute of Cancer Policy, Kings College London, London, United Kingdom bEvaluametrics Ltd., London, United Kingdom cFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia dOncology Europe, Africa, and Middle East Business Unit, Pfizer International Operations, Paris, France ePrevent Cancer Foundation, Alexandria, Virginia fCancer Care, New York, New York gInternational Prevention Research Institute, Lyon, France hNational Cancer Institute Center for Global Health, Bethesda, Maryland iDepartment of Respiratory Medicine, Kings College London, London, United Kingdom jRoy Castle Lung Cancer Foundation, Liverpool, United Kingdom Received 23 October 2015; revised 8 March 2016; accepted 8 March 2016 Available online - 21 March 2016 ABSTRACT significantly behind that of research on other malignancies. Commitment to diagnostics, screening, and quality of life Introduction: Lung cancer is the leading cause of years of research is much lower than to basic science and medical life lost because of cancer and is associated with the highest research. The study findings are expected to provide the economic burden relative to other tumor types. Research requisite knowledge to guide future cancer research pro- remains at the cornerstone of achieving improved outcomes grams in lung cancer. of lung cancer. We present the results of a comprehensive analysis of global lung cancer research between 2004 and Ó 2016 International Association for the Study of Lung 2013 (10 years).
    [Show full text]
  • The Journal of Cancer Research
    A HISTORY OF THE JOURNAL CANCER RESEARCH Commemorating the Journal’s 75th Anniversary February 15, 2016 Volume 76 Number 4 Cancer Research 75TH ANNIVERSARY Driving Innovation to Prevent and Cure Cancer 615 Chestnut Street, 17th Floor Philadelphia, PA 19106 215-440-9300 \\ AACRJournals.org www.AACRJournals.org The following history of the journal Cancer Research and its predecessors was written by June Eberharter, production editor for the Archives staff in the AACR Executive Office. June Eberharter died two months before this history was published. She had been managing editor for two AACR journals, Clinical Cancer Research and Molecular Cancer Research, and previously worked at most of the major publishing houses in the Philadelphia area — a mentor and teacher to a generation of editors. In her 13 years at the AACR, she applied her considerable editorial skills toward conquering the disease that ultimately took her life. This publication is dedicated to June. Kathleen Case, AACR Archivist 5 | AACR: THE FOUNDING 6 | THE JOURNAL OF CANCER RESEARCH 7 | THE AMERICAN JOURNAL OF CANCER 8 | CANCER RESEARCH, THE NEW JOURNAL • The Post-World War II Years 9 | THE JOURNAL RESTRUCTURED: 1950-1959 10 | THE JOURNAL MATURES: 1960-1969 • Smoking and Cancer 11 | AACR LEADER PROFILE: HUGH J. CREECH, PHD 12 | DOCUMENTING THE WAR ON CANCER: 1970-1979 13 | A DECADE OF INNOVATION: 1980-1989 14 | AACR LEADER PROFILE: MARGARET FOTI, PHD, MD (HC) 14 | ANTICIPATING THE NEW MILLENIUM: 1990-1999 16 | A NEW CENTURY OF DISCOVERY: 2000-2009 17 | CURRENT INITIATIVES: 2010 AND BEYOND 18 | APPENDIX 1. JOURNAL STATISTICS AND RANKINGS • Journal Citation Reports • The Eigenfactor® • The H-Index and SCImago Journal Rank (SJR) TABLE OF CONTENTS 20 | REFERENCES 4 History of Cancer Research AACR: THE FOUNDING Gaslights illuminated the streets of Washington on the evening of May 7, 1907, when a group of seven scientists with a mission met at the new Willard Hotel.
    [Show full text]
  • JOURNAL of THORACIC ONCOLOGY Official Journal of the International Association for the Study of Lung Cancer
    JOURNAL OF THORACIC ONCOLOGY Official Journal of the International Association for the Study of Lung Cancer AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.2 • Guide for Authors p.4 ISSN: 1556-0864 DESCRIPTION . About the Journal Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance. Authors are also welcome to submit to the journal?s open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports.
    [Show full text]
  • LUNG CANCER an International Journal for Lung Cancer and Other Thoracic Malignancies
    LUNG CANCER An International Journal for Lung Cancer and other Thoracic Malignancies AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.1 • Guide for Authors p.3 ISSN: 0169-5002 DESCRIPTION . Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome. AUDIENCE . Clinical Oncologists, Internists, Radiologists, Radiotherapists, Thoracic Surgeons, Pulmonary Disease Physicians, Pathologists, Epidemiologists, Public Health Specialists. IMPACT FACTOR . 2020: 5.705 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . PubMed/Medline Elsevier BIOBASE Embase Oncology Information Service Current Contents - Clinical Medicine Web of Science Scopus EDITORIAL BOARD . Editor-in-Chief Rolf Stahel, Zurich, Switzerland Deputy Editors Paul Baas, Amsterdam, Netherlands Martin Edelman, Philadelphia, United States of America AUTHOR INFORMATION PACK 29 Sep 2021 www.elsevier.com/locate/lungcan 1 Sanjay Popat, London, United Kingdom Yi-Long Wu, Guangzhou, China Epidemiology and Prevention Maryska Janssen-Heijnen, Venlo, Netherlands Pathology Elisabeth Brambilla, Grenoble, France Stephen Finn, Dublin, Ireland Systemic Treatment Thierry Berghmans, France Byoung Chul Cho, Korea Nicolas Girard, France Isamu Okamoto, Japan Caicun Zhou, China Radiation Oncology Matthias Guckenberger, Zurich, Switzerland Paul van Houtte, Bruxelles, Belgium Suresh Senan, Amsterdam, Netherlands Surgery Fan Yang, Peking University People's Hospital Pneumonology David Baldwin, Nottingham, United Kingdom Radiology and Nuclear Medicine Irene Burger, Zurich, Switzerland Carole A.
    [Show full text]